Bank of America Securities Sticks to Its Sell Rating for Sarepta Therapeutics (SRPT)

In a report released today, Tazeen Ahmad from Bank of America Securities reiterated a Sell rating on Sarepta Therapeutics, with a price target of $19.00.

TipRanks Welcomes a New ETF – NYSE:RANK

• TipRanks has entered a new arena in the investing world, powering the index of an ETF based on its unique data now trading under the ticker RANK on the NYSE.
• RANK tracks the performance of the TipRanks US Momentum Analysts Index, a rules-based index of 50 large U.S. companies.

Ahmad covers the Healthcare sector, focusing on stocks such as Argenx Se, Incyte, and Regeneron. According to TipRanks, Ahmad has an average return of 7.8% and a 60.98% success rate on recommended stocks.

In addition to Bank of America Securities, Sarepta Therapeutics also received a Sell from H.C. Wainwright’s Mitchell Kapoor in a report issued on July 1. However, on July 10, Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (NASDAQ: SRPT).

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $730.8 million and a net profit of $330.96 million. In comparison, last year the company earned a revenue of $744.86 million and had a GAAP net loss of $447.51 million